These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 24828662)

  • 1. LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT.
    Kaufman JM; Amann JM; Park K; Arasada RR; Li H; Shyr Y; Carbone DP
    J Thorac Oncol; 2014 Jun; 9(6):794-804. PubMed ID: 24828662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
    Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
    Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
    Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
    BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas.
    Gao B; Sun Y; Zhang J; Ren Y; Fang R; Han X; Shen L; Liu XY; Pao W; Chen H; Ji H
    J Thorac Oncol; 2010 Aug; 5(8):1130-5. PubMed ID: 20559149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes.
    Singh A; Daemen A; Nickles D; Jeon SM; Foreman O; Sudini K; Gnad F; Lajoie S; Gour N; Mitzner W; Chatterjee S; Choi EJ; Ravishankar B; Rappaport A; Patil N; McCleland M; Johnson L; Acquaah-Mensah G; Gabrielson E; Biswal S; Hatzivassiliou G
    Clin Cancer Res; 2021 Feb; 27(3):877-888. PubMed ID: 33077574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
    Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
    J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors.
    Carretero J; Shimamura T; Rikova K; Jackson AL; Wilkerson MD; Borgman CL; Buttarazzi MS; Sanofsky BA; McNamara KL; Brandstetter KA; Walton ZE; Gu TL; Silva JC; Crosby K; Shapiro GI; Maira SM; Ji H; Castrillon DH; Kim CF; García-Echeverría C; Bardeesy N; Sharpless NE; Hayes ND; Kim WY; Engelman JA; Wong KK
    Cancer Cell; 2010 Jun; 17(6):547-59. PubMed ID: 20541700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.
    Mahoney CL; Choudhury B; Davies H; Edkins S; Greenman C; Haaften Gv; Mironenko T; Santarius T; Stevens C; Stratton MR; Futreal PA
    Br J Cancer; 2009 Jan; 100(2):370-5. PubMed ID: 19165201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
    Di Federico A; De Giglio A; Parisi C; Gelsomino F
    Eur J Cancer; 2021 Nov; 157():108-113. PubMed ID: 34500370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
    Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
    Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV
    Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YAP promotes malignant progression of Lkb1-deficient lung adenocarcinoma through downstream regulation of survivin.
    Zhang W; Gao Y; Li F; Tong X; Ren Y; Han X; Yao S; Long F; Yang Z; Fan H; Zhang L; Ji H
    Cancer Res; 2015 Nov; 75(21):4450-7. PubMed ID: 26363011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas.
    Tsai LH; Chen PM; Cheng YW; Chen CY; Sheu GT; Wu TC; Lee H
    Oncogene; 2014 Jul; 33(29):3851-60. PubMed ID: 23995788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LKB1, TP16, EGFR, and KRAS somatic mutations in lung adenocarcinomas from a Chiba Prefecture, Japan cohort.
    Suzuki Y; Oonishi T; Kudo T; Doi H
    Drug Discov Ther; 2012 Feb; 6(1):24-30. PubMed ID: 22460425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
    Skoulidis F; Byers LA; Diao L; Papadimitrakopoulou VA; Tong P; Izzo J; Behrens C; Kadara H; Parra ER; Canales JR; Zhang J; Giri U; Gudikote J; Cortez MA; Yang C; Fan Y; Peyton M; Girard L; Coombes KR; Toniatti C; Heffernan TP; Choi M; Frampton GM; Miller V; Weinstein JN; Herbst RS; Wong KK; Zhang J; Sharma P; Mills GB; Hong WK; Minna JD; Allison JP; Futreal A; Wang J; Wistuba II; Heymach JV
    Cancer Discov; 2015 Aug; 5(8):860-77. PubMed ID: 26069186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
    Baptiste Oudart J; Garinet S; Leger C; Barlesi F; Mazières J; Jeannin G; Audigier-Valette C; Morot-Sibilot D; Langlais A; Amour E; Mathiot N; Birsen G; Blons H; Wislez M
    Lung Cancer; 2024 Apr; 190():107508. PubMed ID: 38428265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.
    Memmott RM; Gills JJ; Hollingshead M; Powers MC; Chen Z; Kemp B; Kozikowski A; Dennis PA
    Cancer Res; 2008 Jan; 68(2):580-8. PubMed ID: 18199555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.